FDA Advisory Committee Recommends Approval Of Actemra For The Treatment Of Rheumatoid Arthritis

Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).

More: continued here

Filed under: Arthritis on July 31st, 2008